Skip to main content
SpringerLink
Log in

Response of brain tumors to chemotherapy, evaluated in a clinically relevant xenograft model

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Summary

Chemotherapy for brain tumors remains unsatisfactory. Despite increasing participation in clinical trials, there is a clear need for pre-clinical models. Heterotransplantation of surgical specimens directly into the anterior chamber of the nude mouse eye has been demonstrated to produce evaluable xenografts. Drug access in this model is considered to mimic the blood-brain barrier.

Five clinical specimens in 3 children with primitive neuroectodermal tumor/medulloblastoma were the sources of 293 intraocular xenografts (5 cohorts by source). Each tumor-bearing mouse received 1 of 5 drugs or normal saline, by intraperitoneal injection, weekly for 5 weeks. Response was monitored for up to 22 weeks, using a staging system which estimates the proportion of the anterior chamber filled by tumor.

Results were analysed both as response rates (shrinkage in excess of 50%) at the conclusion of the treatment course and as time to tumor progression by the life table method. Comparison of response rates within cohorts by source of xenografts (exact chi-square test for overall and 2-sided Fisher's exact test for paired comparisons) indicated cyclophosphamide to be the most effective single agent. In logrank analyses cyclophosphamide achieved significantly longer delays to progression than all other drugs in one cohort and longer delays than all but diaziquone in 2 other cohorts.

The intraocular xenograft model is a clinically relevant system for the study of therapeutic agents in brain tumors. The effectiveness of intensive dosage cyclophosphamide in a model dependent on access across the blood-aqueous barrier is important and consistent with recent clinical data.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. White L, Sterling-Levis K, Pittman S, Tobias V, Sosula L: A xenograft model for the study of brain tumours. Cancer Therapy and Control 1: 213–224, 1990

    Google Scholar 

  2. White L, Szirth BC, Benedict WF: Evaluation of response to chemotherapy in retinoblastoma heterotransplanted to the eyes of nude mice. Cancer Chemother Pharmacol 23: 63–67, 1989

    PubMed  Google Scholar 

  3. White L, Reed C, Tobias V: Comparison of cyclophosphamide and diaziquone in a retinoblastoma xenograft model. Ophthalm Paediatr Genet 10: 99–105, 1989

    Google Scholar 

  4. Sterling-Levis K, White L, Trickett AE, Gramacho C, Pittman SM, Tobias V: Heterotransplantation of early B-lineage acute lymphoblastic leukaemia using a solubilized attachment matrix (matrigel). Cancer Res 53: 1222–1225, 1993

    PubMed  Google Scholar 

  5. Hsu SM, Raine L, Fanger H: The use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabelled antibody (PAP) procedures. J Histochem Cytochem 29: 577–580, 1981

    PubMed  Google Scholar 

  6. White L, McCowage G, Kannourakis G, Nayanar V, Colnan L, Kellie S, Shaw P, Seshadri S, Lockwood L, Tiedermann K, Toogood I: Dose intensive cyclophosphamide with etoposide and vincristine for pediatric solud tumours: A phase I/II pilot study by the Australia and New Zealand Childhood Cancer Study Group. J Clin Oncol 12: 522–531, 1994

    PubMed  Google Scholar 

  7. Snedecor GW, Cochran WG: Statistical Methods. Iowa State University Press, 1980, pp 107–30 and 194–210

  8. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II Analysis and examples. Br J Cancer 35: 1–39, 1977

    PubMed  Google Scholar 

  9. Chabner BA, Meyers CE, Coleman CN, Johns DG: The clinical pharmacology of antineoplastic agents (first of two parts). N Engl J Med 292: 1107–1113, 1975

    PubMed  Google Scholar 

  10. Neuwelt EA, Frenkel EP, Diehl JT, Vu LH, Hill SA: Reversible osmotic blood brain barrier disruption? Ann Int Med 93: 147–149, 1980

    Google Scholar 

  11. Takada Y, Greig NH, Vistica DT, Rapoport SI, Smith QR: Affinity of antineoplastic amino acid drugs for the large neutral amino acid transporter of the blood-brain barrier. Cancer Chemo Pharm J 29: 89–94, 1991

    Google Scholar 

  12. Donelli MG, Zucchetti M, D'Incalci M: Do anticancer agents reach the tumor target in the human brain? Cancer Chemo Pharm 30: 251–260, 1992

    Google Scholar 

  13. Shapiro WR, Yung WKA, Basler GA, Shapiro JR: Heterogeneous response to chemotherapy of human gliomas grown in nude mice and as clonesin vitro. Cancer Treat Rep 65: 55–59, 1981

    Google Scholar 

  14. Yung WKA, Shapiro JR, Shapiro WR: Heterogeneous chemosensitivities of subpopulations of human glioma cells in culture. Cancer Res 42: 992–998, 1982

    PubMed  Google Scholar 

  15. Unsgaard G, Helseth E, Vik R, Dalen A: An isotope agarose assay for rapid testing of the sensitivity of glioma biopsies to chemotherapeutic drugs and biological response modifiers. Effects of BCNU, vincristine, lymphokines and recombinant agents Interferon alpha2c, interferon gamma and tumor necrosis factor. Acta Neurochir 91: 60–66, 1988

    Google Scholar 

  16. Dodion F, Sanders C, Georges P, Kenis Y:In vitro chemosensitivity of brain tumors to cisplatin and its analogues, proplatin and carboplatin. Cancer Chemother Pharmacol 22: 80–82, 1988

    PubMed  Google Scholar 

  17. Nikkhah G, Darling JL, Thomas DGT: The application of the MTT chemosensitivity assay to short-term cell lines derived from gliomas characterization and comparison with a35S-methionine uptake assay. Reg Cancer Treat 2: 112–118, 1989

    Google Scholar 

  18. Nikkhah G, Tonn JC, Hoffmann O, Kraemer H-P, Darling JL, Schonmayr R, Schachenmayr W: The MTT assay for chemosensitivity testing of human tumors of the central nervous system. J Neuro-Oncol 13: 1–11, 1992

    Google Scholar 

  19. Schold SC, Friedman HS, Bjornsson TD, Bigner DD: Treatment of human glioma and medulloblastoma tumor lines in athymic mice with diaziquone-based drug combinations. Cancer Res 44: 2352–2357, 1984

    PubMed  Google Scholar 

  20. Horowitz ME, Phaham DM, Douglass EC, Kun LE, Houghton JA, Houghton PJ: Development and characterization of human ependymoma xenograft HxBr5. Cancer Res 47: 499–504, 1987

    PubMed  Google Scholar 

  21. Felker GM, Friedman HS, Dolan ME, Moschel RC, Schold C: Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother Pharmacol 32: 471–476, 1993

    PubMed  Google Scholar 

  22. Miyamachi K: Chemotherapy responsiveness of brain tumors in subrenal capsule assay. Hokkaido Igaku Zasschi 65: (1) 41–49, 1990

    Google Scholar 

  23. Houchens DP, Ovejera AA, Riblet SM, Slagel DE: Human brain tumour xenografts in nude mice as a chemotherapy model. Eur J Cancer Clin Oncol 19: 799–805, 1983

    PubMed  Google Scholar 

  24. Schold SC, Rawlings CE, Bigner SH, Bigner DD: Intracerebral growth of human glioma tumor line in athymic mice and treatment with procarbasine, 1,3-bis(2-chloroethyl)-1-nitrosourea, aziridinylbenzoquinone, ans cis-platinum. Neurosurgery 12: 673, 1983

    Google Scholar 

  25. Friedman HS, Colvin OM, Ludeman SM, Schold SC, Boyd VL, Muhlbaier LH, Bigner DD: Experimental chemotherapy of human medulloblastoma with classical alkylators Cancer Res 46: 2827–2833, 1986

    PubMed  Google Scholar 

  26. Friedman HS, Schold SC, Bigner DD: Chemotherapy of subcutaneous and intracranial human medulloblastoma xenografts in athymic nude mice. Cancer Res 46: 224–228, 1988

    Google Scholar 

  27. Friedman HS, Colvin OM, Shapek SX, Ludeman SM, Elion GN, Schold SC, Jacobsen PF, Muhlbaier LH, Bigner DD: Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents Cancer Res 48: 4189–4195, 1988

    PubMed  Google Scholar 

  28. Friedman HS, Colvin OM, Griffith OW, Lippitz B, Elion GB, Schold SC, Hilton J, Bigner DD: Increased melphalan activity in intracranial human medulloblastoma and glioma xenografts following buthionine sulfoxamine-mediated glutathione depletion. J Natl Cancer Inst 81: 524–527, 1989

    PubMed  Google Scholar 

  29. Kaye AH, Morstyn G, Gardner I, Pyke K: Development of a xenograft glioma model in mouse brain. Cancer Res 46: 1367–1373, 1986

    PubMed  Google Scholar 

  30. Bito LZ: The physiology and pathophysiology of intraocular fluids. Exp Eye Res 25: 273–289, 1977

    PubMed  Google Scholar 

  31. Gardner SK: Ocular drug penetration and pharmacokinetic principles. In: Lamberts DW, Potter DE (eds) Clinical Ophthalmic Pharmacology. Little, Brown and Co, Boston, MA, 1988, pp 1–52

    Google Scholar 

  32. Davson H: The aqueous tumour and intraocular pressure. In: Davson H (ed) Physiology of the Eye, Macmillan Press, London, 1990, pp 3–95

    Google Scholar 

  33. White L, Gomer CJ, Doiron DR, Szirth BC: Ineffective photodynamic therapy (PDT) in a poorly vascularized xenograft model. Br J Cancer 57: 455–58, 1988

    PubMed  Google Scholar 

  34. Walker RW, Allen JC: Cisplatin in the treatment of recurrent childhood primary brain tumors. J Clin Oncol G: 62–66, 1988

    Google Scholar 

  35. Alien J, Walker R, Luks E, Jennings M, Barfoot S, Tan C: Carboplatin and recurrent childhood brain tumours. J Clin Oncol 5: 459–463, 1987

    PubMed  Google Scholar 

  36. Kovnar EH, Kellie SJ, Horowitz ME, Sanford RA, Langsten JW, Mulhern RK, Jenkins JJ, Douglass EC, Etcubanas EE, Fairclough DL, Kun LE: Preirradiation cisplatin and etoposide in the treatment of high-risk medulloblastoma and other malignant embryonal tumors of the central nervous system: A phase II study. J Clin Oncol 8: 330–336, 1990

    PubMed  Google Scholar 

  37. Castello MA, Clerico A, Deb G, Dominici C, Fidani P, Donfrancesco A: High-dose carboplatin in combination with etoposide (JET Regimen) for childhood brain tumors. Am J Pediatr Hematol Oncol 12: 297–300, 1990

    PubMed  Google Scholar 

  38. Friedman HS, Krischer JP, Burger P, Oakes WJ, Hockenberger B, Weiner MD, Falletta JM, Nords D, Ragab AH, Mahoney DH, Whitehead MV, Kun LE: Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin. A pediatric oncology group randomized phase II study. J Clin Oncol 10: 249–256, 1992

    PubMed  Google Scholar 

  39. Gaynon PS, Ettinger LJ, Baum ES, Siegel SE, Krailo MD, Hammond GD: Carboplatin in childhood brain tumors cancer 66: 2465–2468, 1990

    PubMed  Google Scholar 

  40. Rosenstock JG, Evans AE, Schut LJ: Response to vincristine of recurrent brain tumors in children. J Neurosurg 45: 135–140, 1976

    PubMed  Google Scholar 

  41. Chou F, Khan AH, Driscoll JS: Potential central nervous system antitumour agents: Aziridinylbenzoquinones II. J Med Chem 19: 1302, 1976

    PubMed  Google Scholar 

  42. Ettinger LJ, Ru N, Krailo M, Ruccione KS, Krivit W, Hammond GD: A phase II study of diaziquone in children with recurrent or progressive primary brain tumors: A report from the Childrens Cancer Study Group. J Neuro-Oncol 9: 69–76, 1990

    Google Scholar 

  43. White L: Responsiveness of retinoblastoma to local diaziquone. Studies in a xenograft model. Invest Opthal & Visual Science 31: 787–791, 1990

    Google Scholar 

  44. Allen JC, Helson L: High dose cyclosphosphamide chemotherapy for recurrent CNS tumours in children. J Neurosurg 55: 749–756, 1981

    PubMed  Google Scholar 

  45. Friedman HS, Mahaley MS Jr, Schold SC Jr, Vick NA, Falletta JM, Bullard DE, D'Souza BJ, Khandekar JD, Lew S, Oakes WJ, Bigner DD: Efficacy of vincristine and cyclophosphamide in the therapy of recurrent medulloblastoma. Neurosurgery 18: 335–340, 1986

    PubMed  Google Scholar 

  46. Duffner PK, Horowitz ME, Krischer JP, Friedman HS, Burger PC, Cohen ME, Sanford RA, Mulhern RK, Janes HE, Freeman CR, Scidel FG, Kun LE: Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 328: 1725–1731, 1993

    PubMed  Google Scholar 

  47. White L, Johnston H, Jones R, Mameghan H, Nayanar V, McWhirter W, Kellie S, Waters K, Toogood I: Postoperative chemotherapy without radiation in young children with malignant non-astrocytic brain tumours. A report from the Australia and New Zealand Childhood Study Group (ANZCCSG) Cancer Chemother Pharmacol 32: 403–06, 1993

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Children's Leukaemia and Cancer Research Centre, Prince of Wales Children's Hospital, Sydney, NSW, Australia

    Les White & Katy Sterling-Levis

  2. Department of Radiation Oncology, Prince of Wales Hospital, Sydney, NSW, Australia

    Richard Fisher

  3. Department of Anatomical Pathology, Prince of Wales Hospital, Australia

    Vivienne Tobias

Authors
  1. Les White
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katy Sterling-Levis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard Fisher
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vivienne Tobias
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

White, L., Sterling-Levis, K., Fisher, R. et al. Response of brain tumors to chemotherapy, evaluated in a clinically relevant xenograft model. J Neuro-Oncol 25, 39–47 (1995). https://doi.org/10.1007/BF01054721

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01054721

Key words

Search

Navigation